Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

38.86
+1.132.99%
Volume:511.96K
Turnover:19.70M
Market Cap:5.22B
PE:-11.16
High:38.92
Open:37.73
Low:37.73
Close:37.73
52wk High:49.70
52wk Low:8.77
Shares:134.37M
Float Shares:131.11M
Volume Ratio:0.53
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4823
EPS(LYR):-2.0600
ROE:-64.09%
ROA:-20.64%
PB:5.68
PE(LYR):-18.86

Loading ...

OverviewCompanyNewsFilings

Definium Therapeutics Issues Inducement Stock Options for 32,900 Shares to New Hires

Reuters
·
Aug 18

Definium Therapeutics price target raised to $66 from $57 at RBC Capital

TIPRANKS
·
Aug 17

Definium Therapeutics Price Target Raised to $55.00/Share from $50.00 by Maxim Group

Dow Jones
·
Aug 15

Analysts Conflicted on These Healthcare Names: Definium Therapeutics (DFTX), Ionis Pharmaceuticals (IONS) and Sutro Biopharma (STRO)

TIPRANKS
·
Aug 15

Definium Therapeutics Publishes Corporate Presentation Outlining DT120 ODT Clinical Development Pipeline in Mental Health Indications

Reuters
·
Aug 14

Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says

MT Newswires Live
·
Aug 13

RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 13

U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings

Reuters
·
Aug 13

Sector Update: Healthcare Stocks Advance Late Afternoon

MT Newswires Live
·
Aug 13

Definium Therapeutics Price Target Raised to $66.00/Share from $50.00 by Needham

Dow Jones
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Top Midday Stories: Consumer Prices Rise 3.4% YoY in July; CoreWeave Q2 Loss Narrower Than Expectations

MT Newswires Live
·
Aug 12

Ami Fadia Reiterates Buy on Definium (DFTX) as Strong Phase 3 VOYAGE Data Support Unchanged $50 Price Target

TIPRANKS
·
Aug 12

Exchange-Traded Funds, Equity Futures Gain Pre-Bell Wednesday Amid In-Line Consumer Inflation Data, Tech Gains

MT Newswires Live
·
Aug 12

Definium Therapeutics Posts Phase 3 Voyage Topline Results Presentation

Reuters
·
Aug 12

Definium Therapeutics Shares Jump 22% Premarket After Co's Anxiety Disorder Drug Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Aug 12

Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo

MT Newswires Live
·
Aug 12

Definium Therapeutics Says Anxiety Treatment Met Primary Endpoint in Late-Stage Trial

Dow Jones
·
Aug 12

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 Odt in Generalized Anxiety Disorder

THOMSON REUTERS
·
Aug 12

Definium Therapeutics: Phase 3 Voyage Study of DT120 Odt Met Primary & Key Secondary Efficacy Endpoints

THOMSON REUTERS
·
Aug 12
More